long term side effects of glp-1 receptor agonists The cardiovascular beyond obesity and type 2 diabetes: An anti-atherosclerotic action Full article: Managing the gastrointestinal
Description
doi: 10.1056/NEJMoa1212914 242 PownallHJSchwartzAVBrayGABerkowitzRILewisCEBoykoEJet al
Curr Diabetes Rev 19:3145 Gejl M, Gjedde A, Egefjord L et al (2016) In Alzheimers disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial
Prior drug treatments included antihyperlipidemic agents, antidiabetic agents, antiplatelet agents, antihypertensives, and other anti-obesity agents dispensed up to 24 months before the first dispensation of any GLP-1 RA
Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study
(3) development of next-generation GLP-1 receptor-targeted therapeutics with enhanced specificity and reduced off-target effects [129,130,131,132]
SCALE Obesity and Prediabetes NN8022-1839 Study Group
